share_log

Market-Moving News for February 5th

Benzinga ·  Feb 5 21:49

FDMT: 86% | 4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity In Wet AMD

BRTX: 74% | BioRestorative Therapies Presented At The Orthopaedic Research Society 2024 Annual Meeting, Which Describes Preliminary 26 And 52 Week Blinded Data From The Ongoing Phase 2 Trial Of BRTX-100, In Subjects With Chronic Lumbar Disc Disease

CDIO: 33% | Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment